Unknown PHASE3 INTERVENTIONAL 4-arm NCT04325880

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms: a Randomized Controlled Trial

Sponsor: Mansoura University

Conditions Stent Related Symptoms Ureteral Stent

Interventions Mirabegron 50 MG Placebo oral tablet Solifenacin Succinate 10 MG Tamsulosin

Updated 8 times since 2020 Last updated: Nov 20, 2021 Started: Dec 1, 2021 Primary completion: Jun 1, 2022 Completion: Jul 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Stent Related Symptoms and Ureteral Stent and is currently ongoing. Mansoura University leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Dec 2023 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Dec 2021 — Dec 2023 [monthly]

Recruiting PHASE3

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Recruiting PHASE3
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Apr 2020 — Nov 2020 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mansoura University

Data source: Mansoura University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Al Mansurah, Egypt